AIM: To validate the Montreal classification system for Crohn's disease (CD) and ulcerative colitis (UC) within the Netherlands. METHODS: A selection of 20 de-identified medical records with an appropriate representation of the inflammatory bowel disease (IBD) sub phenotypes were scored by 30 observers with different professions (gastroenterologist specialist in IBD, gastroenterologist in training and IBD-nurses) and experience level with IBD patient care. Patients were classified according to the Montreal classification. In addition, participants were asked to score extra-intestinal manifestations (EIM) and disease severity in CD based on their clinical judgment. The inter-observer agreement was calculated by percentages of correct answers (answers identical to the "expert evaluation") and Fleiss-kappa (κ). Kappa cut-offs: < 0.4-poor; 0.41-0.6-moderate; 0.61-0.8-good; > 0.8 excellent. RESULTS: The inter-observer agreement was excellent for diagnosis (κ = 0.96), perianal disease (κ = 0.92) and disease location in CD (κ = 0.82) and good for age of onset (κ = 0.67), upper gastrointestinal disease (κ = 0.62), disease behaviour in CD (κ = 0.79) and disease extent in UC (κ = 0.65). Disease severity in UC was scored poor (κ = 0.23). The additional items resulted in a good inter-observer agreement for EIM (κ = 0.68) and a moderate agreement for disease severity in CD (κ = 0.44). Percentages of correct answers over all Montreal items give a good reflection of the inter-observer agreement (> 80%), except for disease severity (48%-74%). IBD-nurses were significantly worse in scoring upper gastrointestinal disease in CD compared to gastroenterologists (P = 0.008) and gastroenterologists in training (P = 0.040). Observers with less than 10 years of experience were significantly better at scoring UC severity than observers with 10-20 years (P = 0.003) and more than 20 years (P = 0.003) of experience with IBD patient care. Observers with 10-20 years of experience with IBD patient care were significantly better at scoring upper gastrointestinal disease in CD than observers with less than 10 years (P = 0.007) and more than 20 years (P = 0.007) of experience with IBD patient care. CONCLUSION: We found a good to excellent inter-observer agreement for all Montreal items except for disease severity in UC (poor).
AIM: To validate the Montreal classification system for Crohn's disease (CD) and ulcerative colitis (UC) within the Netherlands. METHODS: A selection of 20 de-identified medical records with an appropriate representation of the inflammatory bowel disease (IBD) sub phenotypes were scored by 30 observers with different professions (gastroenterologist specialist in IBD, gastroenterologist in training and IBD-nurses) and experience level with IBDpatient care. Patients were classified according to the Montreal classification. In addition, participants were asked to score extra-intestinal manifestations (EIM) and disease severity in CD based on their clinical judgment. The inter-observer agreement was calculated by percentages of correct answers (answers identical to the "expert evaluation") and Fleiss-kappa (κ). Kappa cut-offs: < 0.4-poor; 0.41-0.6-moderate; 0.61-0.8-good; > 0.8 excellent. RESULTS: The inter-observer agreement was excellent for diagnosis (κ = 0.96), perianal disease (κ = 0.92) and disease location in CD (κ = 0.82) and good for age of onset (κ = 0.67), upper gastrointestinal disease (κ = 0.62), disease behaviour in CD (κ = 0.79) and disease extent in UC (κ = 0.65). Disease severity in UC was scored poor (κ = 0.23). The additional items resulted in a good inter-observer agreement for EIM (κ = 0.68) and a moderate agreement for disease severity in CD (κ = 0.44). Percentages of correct answers over all Montreal items give a good reflection of the inter-observer agreement (> 80%), except for disease severity (48%-74%). IBD-nurses were significantly worse in scoring upper gastrointestinal disease in CD compared to gastroenterologists (P = 0.008) and gastroenterologists in training (P = 0.040). Observers with less than 10 years of experience were significantly better at scoring UC severity than observers with 10-20 years (P = 0.003) and more than 20 years (P = 0.003) of experience with IBDpatient care. Observers with 10-20 years of experience with IBDpatient care were significantly better at scoring upper gastrointestinal disease in CD than observers with less than 10 years (P = 0.007) and more than 20 years (P = 0.007) of experience with IBDpatient care. CONCLUSION: We found a good to excellent inter-observer agreement for all Montreal items except for disease severity in UC (poor).
Entities:
Keywords:
Crohn’s disease; Montreal classification; Phenotypes- inter-observer agreement; Ulcerative colitis
Authors: C Gasche; J Scholmerich; J Brynskov; G D'Haens; S B Hanauer; E J Irvine; D P Jewell; D Rachmilewitz; D B Sachar; W J Sandborn; L R Sutherland Journal: Inflamm Bowel Dis Date: 2000-02 Impact factor: 5.325
Authors: Mark S Silverberg; Jack Satsangi; Tariq Ahmad; Ian D R Arnott; Charles N Bernstein; Steven R Brant; Renzo Caprilli; Jean-Frédéric Colombel; Christoph Gasche; Karel Geboes; Derek P Jewell; Amir Karban; Edward V Loftus; A Salvador Peña; Robert H Riddell; David B Sachar; Stefan Schreiber; A Hillary Steinhart; Stephan R Targan; Severine Vermeire; B F Warren Journal: Can J Gastroenterol Date: 2005-09 Impact factor: 3.522
Authors: Themistocles Dassopoulos; Geoffrey C Nguyen; Alain Bitton; Gillian P Bromfield; L Philip Schumm; Yahong Wu; Abdul Elkadri; Miguel Regueiro; Benjamin Siemanowski; Esther A Torres; Federico J Gregory; Sunanda V Kane; Laura E Harrell; Denis Franchimont; Jean-Paul Achkar; Anne Griffiths; Steven R Brant; John D Rioux; Kent D Taylor; Richard H Duerr; Mark S Silverberg; Judy H Cho; A Hillary Steinhart Journal: Inflamm Bowel Dis Date: 2007-08 Impact factor: 5.325
Authors: L R Sutherland; F Martin; S Greer; M Robinson; N Greenberger; F Saibil; T Martin; J Sparr; E Prokipchuk; L Borgen Journal: Gastroenterology Date: 1987-06 Impact factor: 22.682
Authors: Vineet S Rolston; Anish V Patel; Thomas J Learch; Dalin Li; Dmitry Karayev; Chadwick Williams; Madhavi L Siddanthi; Stephan R Targan; Michael H Weisman; Dermot P B McGovern Journal: J Clin Rheumatol Date: 2019-01 Impact factor: 3.517
Authors: Christopher Andrew Lamb; Nicholas A Kennedy; Tim Raine; Philip Anthony Hendy; Philip J Smith; Jimmy K Limdi; Bu'Hussain Hayee; Miranda C E Lomer; Gareth C Parkes; Christian Selinger; Kevin J Barrett; R Justin Davies; Cathy Bennett; Stuart Gittens; Malcolm G Dunlop; Omar Faiz; Aileen Fraser; Vikki Garrick; Paul D Johnston; Miles Parkes; Jeremy Sanderson; Helen Terry; Daniel R Gaya; Tariq H Iqbal; Stuart A Taylor; Melissa Smith; Matthew Brookes; Richard Hansen; A Barney Hawthorne Journal: Gut Date: 2019-09-27 Impact factor: 23.059
Authors: Tiziana Larussa; Antonio Basile; Caterina Palleria; Chiara Iannelli; Ada Vero; Lidia Giubilei; Caterina De Sarro; Evelina Suraci; Raffaella Marasco; Maria Imeneo; Emilio Russo; Ludovico Abenavoli; Giovambattista De Sarro; Francesco Luzza Journal: Med Pharm Rep Date: 2021-07-29
Authors: Victoria Rai; Cindy Traboulsi; Alexa Silfen; Max T Ackerman; Amarachi I Erondu; Jordan E Karpin; George Gulotta; David T Rubin Journal: Crohns Colitis 360 Date: 2021-08-02
Authors: Maryam Alkhatry; Ahmad Al-Rifai; Vito Annese; Filippos Georgopoulos; Ahmad N Jazzar; Ahmed M Khassouan; Zaher Koutoubi; Rahul Nathwani; Mazen S Taha; Jimmy K Limdi Journal: World J Gastroenterol Date: 2020-11-21 Impact factor: 5.742
Authors: Lieke M Spekhorst; Floris Imhann; Eleonora A M Festen; Ad A van Bodegraven; Nanne K H de Boer; Gerd Bouma; Herma H Fidder; Geert d'Haens; Frank Hoentjen; Daan W Hommes; Dirk J de Jong; Mark Löwenberg; P W Jeroen Maljaars; Andrea E van der Meulen-de Jong; Bas Oldenburg; Marieke J Pierik; Cyriel Y Ponsioen; Pieter C Stokkers; Hein W Verspaget; Marijn C Visschedijk; C Janneke van der Woude; Gerard Dijkstra; Rinse K Weersma Journal: BMJ Open Date: 2017-11-08 Impact factor: 2.692